hotspot -WSS

hotspot

author：knowledge 2025-09-30 01:02:08 - browse：29

Person wearing a smart watch. -- first opinion coverage from STAT — Adobe

The Apple Watch has secured a new qualification from the Food and Drug Administration that could make the smartwatch an appealing tool for medical device companies hoping to illustrate the benefits of a common heart procedure.

Last week, the Apple Watch’s Atrial Fibrillation History feature became the first digital tool qualified under the Medical Device Development Tools (MDDT) program. Released in 2022, the feature estimates a user’s A-fib burden, or how much time they spend in atrial fibrillation, which is an irregular heart rhythm that can cause shortness of breath and fatigue, and is also linked to an increased risk of stroke.

The qualification means that FDA has determined in advance that sponsors can use the feature as a secondary endpoint in clinical trials without having to do additional work. Specifically, the Apple Watch is qualified for use as a secondary endpoint in clinical trials for cardiac ablation devices, which reduce the electrical signals that cause A-fib by scarring the heart with extreme heat or cold energy. Pulsed field ablation is the latest version of the technology, using a controlled electric field to scar tissue rather than the riskier thermal energy.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The high cost of giving birth even with insurance
Next article： Pharma budget tightening trickles down to Doximity

entertainment

WSS

O'Shea Sibley was killed after expressing queer joy by voguing, activists say

Listen: Your guide to Wegovy's blockbuster heart study

Cue Health, Covid

Scrutiny of post

Fentanyl is making it harder to start addiction treatment

Study finds gene variants tied to breast cancer risk in Black women

explore

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

hotspot

Peter Hotez and the public health issue of online harassment

An innovative path out of biotech’s “valley of death”

Heart attack and stroke risk calculators need revising

H5N1 bird flu outbreak: Second human case reported, in Michigan

Affirmative action in medical school literally saved lives

For longer

Trump demands the U.S. pay no more for drugs than other countries … again

Readout Newsletter: Eli Lilly, AstraZeneca, Bristol Meyers Squibb

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

White House drug shortages task force keeps mum with Congress

hotspot

Making the case for fair compensation in clinical trials

The history of OxyContin, told through Purdue Pharma documents

H5N1 virus can be tracked in retail milk, scientists say

Investigation reveals sickle cell patients pressured into sterilizations

Scrutiny of post

Iran moves toward freeing 5 American citizens who had been imprisoned, in rare deal

knowledge

focus

entertainment

hotspot